Emerging therapeutic options for the management of hepatitis C infection

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 23

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 21, 2014; 20(23): 7079-7088
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7079

Table 1 Protease inhibitors currently under development

First generation (wave 2)

Simeprevir

Faldaprevir

Danoprevir

Vaniprevir

ABT-450/ABT-450r

Asunaprevir

Second generation

MK-5172

ACH-2684

Citation: Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol 2014; 20(23): 7079-7088
URL: https://www.wjgnet.com/1007-9327/full/v20/i23/7079.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i23.7079

Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol 2014; 20(23): 7079-7088 [PMID: 24966581 DOI: 10.3748/wjg.v20.i23.7079]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.